Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder

Next Previous
Trial Profile

A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder

Status: Discontinued
Phase of Trial: Phase III/IV

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization

Most Recent Events

  • 23 Dec 2020 Number of treatment arms has been increased from 2 to 4 and treatments section is modified to include 3 double-blind phase arms of Aripiprazole-full dose, half dose and placebo, and an open label stabilization phase arm of Aripiprazole.
  • 10 Jul 2020 Status changed from active, no longer recruiting to discontinued.
  • 11 Jun 2020 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top